PMID- 28736629
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240326
IS  - 2078-6891 (Print)
IS  - 2219-679X (Electronic)
IS  - 2078-6891 (Linking)
VI  - 8
IP  - 3
DP  - 2017 Jun
TI  - Biologic therapy in esophageal and gastric malignancies: current therapies and 
      future directions.
PG  - 418-429
LID - 10.21037/jgo.2016.11.13 [doi]
AB  - Biologic agents, including targeted antibodies as well as immunomodulators, are 
      demonstrating unparalleled development and study across the entire spectrum of 
      human malignancy. This review summarizes the current state of biologic therapies 
      for esophageal, esophagogastric, and gastric malignancies, including those that 
      target human epidermal growth factor receptor 2 (HER2), epidermal growth factor 
      receptor (EGFR), vascular endothelial growth factor (VEGF), c-Met, mechanistic 
      target of rapamycin (mTOR) and immunomodulators. We focus primarily on agents 
      that have been included in phase II and III clinical trials in locally advanced, 
      progressive, or metastatic esophageal and gastric malignancies. At this time, 
      only two biologic therapies are recommended by the National Comprehensive Cancer 
      Network (NCCN): trastuzumab for patients with esophageal/esophagogastric or 
      gastric adenocarcinomas with HER2 overexpression and ramucirumab, a VEGFR-2 
      inhibitor, as a second-line therapy for metastatic disease. However, recent 
      reports of increases in overall and progression-free survival for agents 
      including pertuzumab, apatinib, and pembrolizumab will likely increase the use of 
      targeted biologic therapy in clinical practice for esophageal and gastric 
      malignancies.
FAU - Samson, Pamela
AU  - Samson P
AD  - Division of Cardiothoracic Surgery, Washington University in St. Louis, St. 
      Louis, MO, USA.
FAU - Lockhart, A Craig
AU  - Lockhart AC
AD  - Division of Oncology, Washington University in St. Louis, St. Louis, MO, USA.
LA  - eng
GR  - T32 HL007776/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - China
TA  - J Gastrointest Oncol
JT  - Journal of gastrointestinal oncology
JID - 101557751
PMC - PMC5506284
OTO - NOTNLM
OT  - Esophageal cancer
OT  - biologic therapy
OT  - gastric cancer
OT  - immunomodulator therapy
COIS- Conflicts of Interest: The authors have no conflicts of interest to declare.
EDAT- 2017/07/25 06:00
MHDA- 2017/07/25 06:01
PMCR- 2017/06/01
CRDT- 2017/07/25 06:00
PHST- 2017/07/25 06:00 [entrez]
PHST- 2017/07/25 06:00 [pubmed]
PHST- 2017/07/25 06:01 [medline]
PHST- 2017/06/01 00:00 [pmc-release]
AID - jgo-08-03-418 [pii]
AID - 10.21037/jgo.2016.11.13 [doi]
PST - ppublish
SO  - J Gastrointest Oncol. 2017 Jun;8(3):418-429. doi: 10.21037/jgo.2016.11.13.